Inflammatory conditions like rheumatoid arthritis, inflammatory bowel disease and psoriasis can reduce your patients’ quality of life and limit their lifestyle choices. Using a biologic anti-TNF treatment can help your patients to...

rewrite their story

Hulio® (adalimumab) is used to treat a number of autoimmune inflammatory disorders when other treatments have failed.

About Hulio®

Hulio® is an approved biosimilar of adalimumab and is the third tumour necrosis factor (TNF)-blocking agent available as a biosimilar after infliximab and etanercept for the management of immune-mediated diseases in children and adults.

Hulio® is a recombinant human monoclonal antibody (mAB). The active substance is adalimumab. Adalimumab is the third tumour necrosis factor alpha (TNFα)-blocking agent available in the form of a biosimilar, following infliximab (another monoclonal antibody, mAb) and etanercept (a fusion protein).1

Learn more

How to use
Hulio®

Hulio® is available in 3 presentations including a pre-filled pen for patient convenience.

Learn more

How Hulio®
works

Hulio® is a recombinant human monoclonal antibody that helps to reduce the symptoms of immune-mediated diseases in children and adult population, such as moderate-to-severe active rheumatoid arthritis (RA), moderate-to-severe chronic plaque psoriasis (Pso) and inflammatory bowel disease (IBD: Crohn’s disease and ulcerative colitis).

Learn more

Dosing

Hulio® has been approved for the treatment of immune-mediated conditions among children and adults. The dosage of Hulio in adults depends on the immune-mediated condition they are being treated for. In children, dosage depends on their body weight too. Please refer to the Hulio® SmPC for full prescribing information

Learn more

Restricted access

The website you are trying to access is designed for healthcare professionals only - the content is not designed for the general public.

Are you a healthcare professional based in UK or Ireland?

YES
NO

Report side effects

Healthcare professionals are asked to report any suspected adverse reactions via: UK: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.  Adverse events should also be reported to Mylan via info@mylan.co.uk.

You are now leaving the Hulio® uk website